Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23627653 | 0.91 | FOLH1 (0.36) | FOLH1TYR | |
| SCHEMBL25488445 | 0.90 | FOLH1 (0.31) | FOLH1 | |
| SCHEMBL20465431 | 0.90 | L3MBTL1 (0.35) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL18452620 | 0.90 | L3MBTL1 (0.35) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL20465446 | 0.80 | FOLH1 (0.36) | FOLH1TYR | |
| SCHEMBL20465441 | 0.80 | FOLH1 (0.36) | FOLH1TYR | |
| SCHEMBL20465444 | 0.80 | FOLH1 (0.31) | FOLH1 | |
| SCHEMBL20465423 | 0.80 | FOLH1 (0.31) | FOLH1 | |
| SCHEMBL21469698 | 0.79 | FOLH1 (0.38) | FOLH1TYR | |
| SCHEMBL20468580 | 0.78 | FOLH1 (0.32) | FOLH1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023081832-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | L3MBTL1 627/4885KMT2A 1913/4885POLB 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.